Delayed luteolysis and suppression of the pulsatile release of oxytocin after indomethacin treatment in the goat.
Luteolysis in the goat was characterised by the pulsatile appearance of both oxytocin and 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM), the primary pulmonary metabolite of prostaglandin (PG) F2 alpha, in the peripheral circulation. The episodic, surge release of oxytocin was superimposed on declining levels which paralleled the fall in progesterone concentrations. Daily subcutaneous administration of the prostaglandin synthetase inhibitor indomethacin (10 mg kg-1) between days 11 and 16, delayed luteolysis and suppressed both the decline in oxytocin concentrations and the pulsatile appearance of both oxytocin and PGFM in the peripheral circulation. Although there was little evidence of the release of the two hormones being synchronised, the results suggest that PGF2 alpha may stimulate pulsatile oxytocin release at luteolysis.
D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects*; D015237:Dinoprost / Q000031:analogs & derivatives*; D004971:Estrus / Q000187:drug effects; D005260:Female; D006041:Goats / Q000502:physiology*; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology*; D007279:Injections, Subcutaneous / Q000662:veterinary; D003341:Luteolysis / Q000187:drug effects*; D010121:Oxytocin / Q000097:blood*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011460:Prostaglandins F / Q000097:blood*; D011863:Radioimmunoassay
D011460:Prostaglandins F; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost; D007213:Indomethacin